[Evaluation of the use of calcitonin in rheumatoid arthritis by bone densitometry and the study of of phospho-calcium metabolism].
Forty-eight patients were subdivided into three groups according to the stage of their rheumatoid arthritis and to whether or not they received glucocorticoids; they were compared to healthy volunteers of similar sex, age, and body weight. Before calcitonin treatment, bone mineral content (BMC) of RA patients was significantly lowered, especially in patients with 3rd and 4th Steinbroker degree and in those taking glucocorticoids. Synthetic eel calcitonin was administered in three 60-day cycles separated by 40-day intervals with daily dosage 40 U.M.R.C. (1 vial). This treatment did not result in a increase of BMC compared to baseline. A further decrease of BMC observed at the end of treatment was not statistically significant. No appreciable variation was found in parameters of phospho-calcic metabolism.